Asia Outlook 2019
After the volatility that defined much of 2018, capital market bankers in Asia started the year full of trepidation. Would the Federal Reserve speed up its slow-motion rate rises? Would Chinese defaults become a major problem? Would investors extend the period of hibernation they began during the bearish end to last year?
Foreign investors and issuers are facing big hurdles in navigating China’s Rmb87tr ($12tr) bond market, and the even more complicated regulatory network around it. But the situation is improving and both sides still have plenty to learn from each other. Rebecca Feng reports.
India's capital markets started 2019 with much more vigour than they ended 2018, but a looming election is set to apply the brakes. Will the contest derail issuance for much of the year or be little more than a temporary blip? Bankers tell Morgan Davis they are optimistic
Pakistan walks a fine line between emerging market and frontier. It is clinging on to its hard won status, reports Morgan Davis
Chinese property companies dominate Asia’s high yield bond market like never before. But rising volumes bring rising risks — and maturities are looming. Addison Gong reports
Chinese banks will require a helping hand to comply with international standards on loss-absorbing capacity, as they go from being part-time users of the global capital markets to big players in debt financing. Luckily for them, domestic regulators appear increasingly keen for the banking sector to be recapitalised. Tyler Davies reports
Asia's green bond market is facing a familiar problem: plenty of potential issuers, too few investors. But the market is finding its place — and bankers are discovering ways to develop sustainable finance beyond just green bonds. Morgan Davis reports
The year started with a few headwinds for China-focused loans bankers, including uncertainties coming from the US-China trade war, rising bond and loan defaults and reduced Taiwanese liquidity. But with huge refinancing needs and a volatile bond market, many are anticipating a promising year. Pan Yue reports.
Hong Kong’s stock exchange took a progressive step in 2018 when it allowed pre-revenue biotechnology companies to list. But the initial excitement was short lived, with the stocks’ dismal performance in the aftermarket denting sentiment among issuers, bankers and investors. Will the tide turn for the sector this year? Jonathan Breen investigates.
Stricter financial disclosure rules, a corruption scandal and a global equity market selloff derailed what should have been a big year for South Korean IPOs last year, leading to three of the biggest transactions being postponed. There are reasons for hope, but the country must overcome some serious structural challenges. Aidan Gregory reports
Publisher: Oliver Hawkins
Telephone: +44(0)20 7779 7304
Deputy Publisher: James Andrews
Telephone: +44 (0)20 7779 8074
Associate Publisher: Daniel Elton
Telephone: +44 (0)20 7779 7305
US Publisher: Kevin Dougherty
Telephone: +1 212 224 3445